News >

Multimodality Treatment Linked to High OS Rate in Pediatric RMS of Head and Neck

Jason Harris
Published: Tuesday, Nov 28, 2017

An adjusted combination of chemotherapy, radiation therapy, and surgery induced a 5-year overall survival (OS) rate of 91.3% in pediatric patients with rhabdomyosarcomas (RMS) of the head and neck.

Common side effects associated with chemotherapy and radiation therapy included neutropenia, mucositis, nausea and vomiting, and radiodermatitis. One patient had a secondary malignancy, a radiation-induced sarcoma of the right pterygopalatine fossa treated with ifosfamide, topotecan, and cyclophosphamide.
Häußler SM, Stromberger C, Olze, et al. Head and neck rhabdomyosarcoma in children: a 20-year retrospective study at a tertiary referral center [published online November 16, 2017]. J Cancer Res Clin Oncol. doi: 10.1007/s00432-017-2544-x.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication